Pain, Radiating
Conditions
Keywords
cervical, radicular pain, transforaminal epidural steroid injections
Brief summary
Cervical radicular pain is a common cause of disability and pain in the upper extremity and neck with an annual incidence of 83.2/100,000 (1). The initial treatment is conservative and includes relative rest, use of anti-inflammatory and analgesic medication, as well as physical therapy and home exercise. For patients who have persistent and significant symptoms, interventional pain management and surgical management are considered. Cervical epidural injections are the mainstay of the interventional, non-surgical modalities. They can be considered to provide short and long-term relief when disc herniation, foraminal stenosis or central canal stenosis pathology is identified. We are not aware of any published prospective, randomized, controlled, double-blinded studies demonstrating the efficacy of cervical transforaminal epidural steroid injections. However, the North American Spine Society (NASS) Review and Recommendation Statement states that based on the literature and expert opinion, a minimum of one or two cervical epidural steroid injections would be very appropriate in the treatment of a specific episode of cervical radicular pain. The purpose of this study is to determine the effectiveness of cervical transforaminal epidural steroid injections in decreasing the need for an operation in patients with cervical radicular pain, otherwise considered to be operative candidates.
Detailed description
Cervical radicular pain is a common cause of disability and pain in the upper extremity and neck with an annual incidence of 83.2/100,000 (1). The initial treatment is conservative and includes relative rest, use of anti-inflammatory and analgesic medication, as well as physical therapy and home exercise. For patients who have persistent and significant symptoms, interventional pain management and surgical management are considered. Cervical epidural injections are the mainstay of the interventional, non-surgical modalities. They can be considered to provide short and long-term relief when disc herniation, foraminal stenosis or central canal stenosis pathology is identified. Cervical epidural injections can be performed by two different approaches, transforaminal and interlaminar. Transforaminal epidural injections allow delivery of medication to the ventral epidural space, while the interlaminar approach reaches the ventral epidural space in only 28% of injections (2-4). The results of cervical epidural injections remain controversial and their efficacy in decreasing the need for surgery in patients who would otherwise be operative candidates has not been thoroughly investigated. Studies have been limited by small sample sizes, lack of control groups, and lack of randomization. Kolstad et al reported that 23% (5/21) of patients waiting for cervical disc surgery cancelled surgery when assessed at four months after having a series of two cervical epidural injections (6). Lin et al reported that 63% (44/70) of patients who were deemed to be surgical candidates were able to avoid surgery with an average of 13-month follow up (7). Lee et al reported that over 80% of 98 patients evaluated with cervical radiculopathy were able to avoid surgery with a 2-year follow-up (8). Anderberg et al reported that there was no short-term difference in symptoms of cervical radiculopathy between patients who received transforaminal injections of steroid with local anesthetic versus saline with local anesthetic. However, this study did not evaluate whether the injections were successful in the patients avoiding surgery (11). In terms of lumbar transforaminal epidural injections, Riew et al demonstrated that steroid injections obviated the need for surgery in patients with lumbar radiculopathy. Moreover, Reiw et al showed that steroid combined with local anesthetic was more effective than local anesthetic alone in a prospective, randomized, controlled, double-blinded study (9). Riew et al later studied the efficacy of cervical transforaminal epidural injections in the same fashion, but the findings were not statistically significant (p\<0.35) and not published (10). We are not aware of any published prospective, randomized, controlled, double-blinded studies demonstrating the efficacy of cervical transforaminal epidural steroid injections. However, the North American Spine Society (NASS) Review and Recommendation Statement states that based on the literature and expert opinion, a minimum of one or two cervical epidural steroid injections would be very appropriate in the treatment of a specific episode of cervical radicular pain. This literature also suggests that a maximum of four injections can be used within six months, assuming there was a positive response and improvement seen with the previous injections.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Subjects who have cervical radicular pain without significant neurologic deficit (neurologic deficit is defined as manual muscle testing less than 3/5), MRI/CT findings of neural compression (neural compression is defined as disc herniation or central or foraminal spinal stenosis), * Failed 6 weeks of conservative treatment (conservative treatment is defined as relative rest, home exercise, physical therapy, and use of anti-inflammatory and/or analgesic medications), * Deemed to be good operative candidates by spine surgeons (patients with MRI/CT findings of neural compression with concordant symptoms) and had agreed to possible operative intervention
Exclusion criteria
* History of 1. acute trauma, 2. diabetes (type I or type II), 3. active infection * Active progressive neurological deficit (neurologic is deficit defined as manual muscle testing less than 3/5), * Medical condition that may affect the cervical spine neurological exam and/or pain assessment (e.g. peripheral neuropathy), * Bilateral disease, * More than one cervical level requiring injection, * Bleeding disorders or other medical contraindications to the injection procedure, * Absence of substantial radicular pain (radicular pain is defined as arm pain greater than neck pain), * Involvement in workers' compensation claim, or any litigation related to neck injury. * Patients who are pregnant, or who plan to become pregnant in the next 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Avoidance of Neck Surgery | 12 months after the first injection | The primary outcome variable is the avoidance of surgery. Treatment success is defined as the avoidance of surgery, while treatment failure is defined as having surgery due to failure of the injection treatment to alleviate pain and improve function over the 12 months they are being followed for purposes of this study. Avoided neck surgery noted as 'Yes'; avoided neck surgery 'No' the patient had neck surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disability | 4 weeks | Neck Disability Index (NDI) - The NDI consists of 10 questions. Each of the 10 items is scored from 0 (minimum) - 5(maximum). The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score (i.e. a score of 50 indicates 100% disability). Scores are reported as the percentage (i.e. 100 is the max score for data presented). |
| Numeric Pain Scre | 4 weeks | Verbal Numeric Pain Scale (VNPS) -Scaled 0-10 with 10 being worst imaginable pain and 0 being no pain |
| Patient Satisfaction | 4 weeks | Patient satisfaction with the treatment. Scale is an inverse of verbal numeric pain score. A 0 on VNPS equates to a 10 on patient satisfaction, 10 on VNPS equates to 0 on patient satisfaction |
| Numeric Pain Score | 12 weeks | Verbal Numeric Pain Scale-Scaled 0-10 with 10 being worst imaginable pain and 0 being no pain |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lidocaine Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
Lidocaine | 27 |
| Lidocaine With Dexamethasone Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
Lidocaine with Dexamethasone | 26 |
| Total | 53 |
Baseline characteristics
| Characteristic | Total | Lidocaine | Lidocaine With Dexamethasone |
|---|---|---|---|
| Age, Continuous | 52 years | 50 years | 53.5 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 50 Participants | 26 Participants | 24 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 1 Participants | 2 Participants |
| Neck Disability Index | 34 units on a scale | 33 units on a scale | 35 units on a scale |
| Patient Satisfaction | 3.5 units on a scale | 5 units on a scale | 3 units on a scale |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 12 Participants | 9 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 38 Participants | 16 Participants | 22 Participants |
| Region of Enrollment United States | 53 participants | 27 participants | 26 participants |
| Sex: Female, Male Female | 32 Participants | 17 Participants | 15 Participants |
| Sex: Female, Male Male | 21 Participants | 10 Participants | 11 Participants |
| Verbal Numeric Pain Score | 6.5 units on a scale | 5 units on a scale | 7 units on a scale |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 27 | 0 / 26 |
| other Total, other adverse events | 3 / 27 | 9 / 26 |
| serious Total, serious adverse events | 0 / 27 | 0 / 26 |
Outcome results
Avoidance of Neck Surgery
The primary outcome variable is the avoidance of surgery. Treatment success is defined as the avoidance of surgery, while treatment failure is defined as having surgery due to failure of the injection treatment to alleviate pain and improve function over the 12 months they are being followed for purposes of this study. Avoided neck surgery noted as 'Yes'; avoided neck surgery 'No' the patient had neck surgery.
Time frame: 12 months after the first injection
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Lidocaine | Avoidance of Neck Surgery | No(had surgery) | 24 Participants |
| Lidocaine | Avoidance of Neck Surgery | Yes (Did not have surgery) | 3 Participants |
| Lidocaine With Dexamethasone | Avoidance of Neck Surgery | No(had surgery) | 20 Participants |
| Lidocaine With Dexamethasone | Avoidance of Neck Surgery | Yes (Did not have surgery) | 6 Participants |
Disability
Neck Disability Index (NDI) - The NDI consists of 10 questions. Each of the 10 items is scored from 0 (minimum) - 5(maximum). The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score (i.e. a score of 50 indicates 100% disability). Scores are reported as the percentage (i.e. 100 is the max score for data presented).
Time frame: 4 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Disability | 25.2 units on a scale | Standard Deviation 14.1 |
| Lidocaine With Dexamethasone | Disability | 22.8 units on a scale | Standard Deviation 17.2 |
Disability
Neck Disability Index- The NDI consists of 10 questions. Each of the 10 items is scored from 0 (minimum) - 5(maximum). The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score (i.e. a score of 50 indicates 100% disability). Scores are reported as the percentage (i.e. 100 is the max score for data presented).
Time frame: 12 Months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Disability | 16.4 units on a scale | Standard Deviation 14.4 |
| Lidocaine With Dexamethasone | Disability | 15.4 units on a scale | Standard Deviation 10.2 |
Disability
Neck Disability Index- The NDI consists of 10 questions. Each of the 10 items is scored from 0 (minimum) - 5(maximum). The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score (i.e. a score of 50 indicates 100% disability). Scores are reported as the percentage (i.e. 100 is the max score for data presented).
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Disability | 25.1 units on a scale | Standard Deviation 15.3 |
| Lidocaine With Dexamethasone | Disability | 18.3 units on a scale | Standard Deviation 18.4 |
Disability
Neck Disability Index- The NDI consists of 10 questions. Each of the 10 items is scored from 0 (minimum) - 5(maximum). The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score (i.e. a score of 50 indicates 100% disability). Scores are reported as the percentage (i.e. 100 is the max score for data presented).
Time frame: 6 Months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Disability | 19.4 units on a scale | Standard Deviation 14 |
| Lidocaine With Dexamethasone | Disability | 16.3 units on a scale | Standard Deviation 17.5 |
Numeric Pain Score
Verbal Numeric Pain Scale-Scaled 0-10 with 10 being worst imaginable pain and 0 being no pain
Time frame: 12 Months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Numeric Pain Score | 2.9 score on a scale | Standard Deviation 2.8 |
| Lidocaine With Dexamethasone | Numeric Pain Score | 3.2 score on a scale | Standard Deviation 3.1 |
Numeric Pain Score
Verbal Numeric Pain Scale-Scaled 0-10 with 10 being worst imaginable pain and 0 being no pain
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Numeric Pain Score | 3.6 score on a scale | Standard Deviation 2.4 |
| Lidocaine With Dexamethasone | Numeric Pain Score | 3.4 score on a scale | Standard Deviation 3 |
Numeric Pain Score
Verbal Numeric Pain Scale-Scaled 0-10 with 10 being worst imaginable pain and 0 being no pain
Time frame: 6 Months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Numeric Pain Score | 3.0 score on a scale | Standard Deviation 2.4 |
| Lidocaine With Dexamethasone | Numeric Pain Score | 2.2 score on a scale | Standard Deviation 2.8 |
Numeric Pain Scre
Verbal Numeric Pain Scale (VNPS) -Scaled 0-10 with 10 being worst imaginable pain and 0 being no pain
Time frame: 4 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Numeric Pain Scre | 3.7 score on a scale | Standard Deviation 2.8 |
| Lidocaine With Dexamethasone | Numeric Pain Scre | 3.8 score on a scale | Standard Deviation 2.9 |
Patient Satisfaction
Patient satisfaction with the treatment. Scale is an inverse of verbal numeric pain score. A 0 on VNPS equates to a 10 on patient satisfaction, 10 on VNPS equates to 0 on patient satisfaction
Time frame: 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Patient Satisfaction | 7.0 score on a scale | Standard Deviation 2.4 |
| Lidocaine With Dexamethasone | Patient Satisfaction | 7.8 score on a scale | Standard Deviation 2.8 |
Patient Satisfaction
Patient satisfaction with the treatment. Scale is an inverse of verbal numeric pain score. A 0 on VNPS equates to a 10 on patient satisfaction, 10 on VNPS equates to 0 on patient satisfaction
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Patient Satisfaction | 6.4 score on a scale | Standard Deviation 2.4 |
| Lidocaine With Dexamethasone | Patient Satisfaction | 6.6 score on a scale | Standard Deviation 3 |
Patient Satisfaction
Patient satisfaction with the treatment. Scale is an inverse of verbal numeric pain score. A 0 on VNPS equates to a 10 on patient satisfaction, 10 on VNPS equates to 0 on patient satisfaction
Time frame: 4 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Patient Satisfaction | 6.3 score on a scale | Standard Deviation 2.8 |
| Lidocaine With Dexamethasone | Patient Satisfaction | 6.2 score on a scale | Standard Deviation 2.9 |
Patient Satisfaction
Patient satisfaction with the treatment. Scale is an inverse of verbal numeric pain score. A 0 on VNPS equates to a 10 on patient satisfaction, 10 on VNPS equates to 0 on patient satisfaction
Time frame: 12 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Patient Satisfaction | 7.2 score on a scale | Standard Deviation 2.8 |
| Lidocaine With Dexamethasone | Patient Satisfaction | 6.8 score on a scale | Standard Deviation 3.1 |